Login to Your Account

Encysive Submits Thelin NDA In PAH, Seeks Accelerated Review

By Aaron Lorenzo

Thursday, May 26, 2005
Encysive Pharmaceuticals Inc. set its lead drug candidate, Thelin (sitaxsentan), on the pathway toward approval for pulmonary arterial hypertension by filing a new drug application with the FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription